• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

    4/11/24 4:30:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ILMN alert in real time by email

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

    "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to our impressive executive team."

    Dr. Ronaghi is the Co-Founder and Executive Board Member of Cellanome. Prior to founding Cellanome, he was Chief Technology Officer, Senior Vice President, and member of the Executive Leadership Team at Illumina, Inc. (NASDAQ:ILMN) from 2008 to 2021. While at Illumina, in 2016, Dr. Ronaghi co-founded GRAIL, a next-gen liquid biopsy platform for cancer detection. Prior to Illumina, Dr. Ronaghi was Principal Investigator at the Stanford Genome Technology Center from 1999 to 2008. Throughout his prolific career, Dr. Ronaghi co-founded several other companies, including Pyrosequencing AB in 1997, ParAllele Biosciences in 2001, NextBio in 2004, Avantome in 2008, and Clear Labs in 2014, each of which sought to increase the understanding of particular diseases through next-generation sequencing (NGS), advanced genotyping, or other advanced technology. Dr. Ronaghi holds a Ph.D. in Biotechnology from Royal Institute of Technology in Stockholm, Sweden.

    "Dr. Ronaghi and his decades of experience building and leading successful organizations will be a tremendous source of wisdom to our executives at Team Summit," added Dr. Maky Zanganeh, Chief Executive Officer, President, and a member of the Board of Directors of Summit.

    "I am very pleased at the opportunity to join Summit's Board of Directors," said Dr. Ronaghi. "This extraordinary team and its mission to increase the quality and duration of patients' lives while reducing trauma is unparalleled. I am optimistic on the potential for ivonescimab to make a meaningful difference to those facing serious unmet medical needs, and I am thrilled to work with Team Summit in order to help it achieve its mission and goals."

    About Ivonescimab

    Ivonescimab, known as SMT112 in Summit's license territories, the United States, Canada, Europe, and Japan, and as AK112 in China and Australia, is an investigational, novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays cooperative binding with each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.

    This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab's tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the tumor microenvironment with over 18-fold increased binding affinity to PD-1 in the presence of VEGF in vitro, and over 4-times increased binding affinity to VEGF in the presence of PD-1 in vitro (Zhong, et al, SITC, 2023). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets.

    Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III clinical trials. Over 1,600 patients have been treated with ivonescimab in clinical studies globally. Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), commencing enrollment in 2023 in two Phase III clinical trials.

    Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

    About Summit Therapeutics

    Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

    Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT'). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.

    For more information, please visit https://www.smmttx.com and follow us on X @summitplc.

    Summit Forward-looking Statements

    Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc., the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, potential acquisitions, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240411264216/en/

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Summit Therapeutics Inc.
    $SMMT
    7/1/2025$30.00Buy
    UBS
    Summit Therapeutics Inc.
    $SMMT
    6/11/2025$12.00Underperform
    Leerink Partners
    Summit Therapeutics Inc.
    $SMMT
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ILMN
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Summit Therapeutics with a new price target

    Barclays initiated coverage of Summit Therapeutics with a rating of Underweight and set a new price target of $13.00

    9/17/25 8:03:56 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Summit Therapeutics with a new price target

    Guggenheim initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $40.00

    9/4/25 9:07:53 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Summit Therapeutics with a new price target

    Piper Sandler initiated coverage of Summit Therapeutics with a rating of Neutral and set a new price target of $21.00

    8/19/25 8:35:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/19/25 4:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:36:31 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:32:04 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:36:31 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:32:04 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on September 18, 2025. The options have a ten (10) year term and an exercise price of $19.23 per share, the closing price per share of the Company's common stock as reported by Nasdaq on

    9/24/25 4:30:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

    Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Symposium at the European Society for Medic

    9/24/25 7:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina advances personalized cancer care with new pharma development partnerships

    Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.

    9/23/25 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    SEC Filings

    View All

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    9/8/25 7:45:14 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 5:13:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Summit Therapeutics Inc.

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 4:51:33 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

    Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

    3/25/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Financials

    Live finance-specific insights

    View All

    Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

    With Longer-Term Follow-Up of Western Patients, Ivonescimab Plus Chemotherapy Demonstrated Improving Global OS Trend with Nominal p-value of 0.0332 vs. Chemotherapy Alone; North American Patients' OS HR=0.70 Consistent Median Overall Survival Observed in Western, Asian Patients in Longer-Term Follow-Up Analysis of Western Patients Presented at Presidential Symposium at WCLC 2025 Conference Call to be Held at 8:00am ET on Monday, September 8, 2025 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was prese

    9/7/25 3:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

    Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China; Ivonescimab Monotherapy Approved by NMPA in China for 1L PD-L1 Positive Advanced NSCLC Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant, Clinically Mea

    8/11/25 5:03:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

    Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include

    7/31/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care